Abstract:A reduction in both dystrophin and neuronal nitric oxide synthase (NOS1) secondary to microRNA-31 (miR-31) upregulation contributes to the atrial electrical remodelling that underpins human and experimental atrial fibrillation (AF). By contrast, patients with Duchenne Muscular Dystrophy (DMD), who lack dystrophin and NOS1 and, at least in the skeletal muscle, have raised miR-31 expression, do not have increase susceptibility to AF in the absence of left ventricular (LV) dysfunction. Here we investigated whether dystrophin-deficiency is also associated with atrial upregulation of miR-31, loss of NOS1 protein, and increased AF susceptibility in young mdx mice. Echocardiography showed normal cardiac structure and function in 12- 13 weeks mdx mice, with no indication by assay of hydroxyproline that atrial fibrosis had developed. Absence of dystrophin in mdx mice was accompanied by an overall reduction in syntrophin and a lower NOS1 protein content in the skeletal muscle and in the left atrial and ventricular myocardium, with the latter occurring alongside reduced Nos1 transcript levels (exons 1-2 by qPCR) and an increase in NOS1-polyubiquitination (assessed using tandem polyubiquitination pulldowns; P<0.05 vs. WT). Neither the upregulation of miR-31 nor the substantial reduction in NOS activity observed in the skeletal muscle was present in the atrial tissue of mdx mice. At difference with the skeletal muscle, the mdx atrial myocardium showed a reduction in the constitutive NOS inhibitor, caveolin-1, coupled with an increase in NOS3 serine 1177 phosphorylation, in the absence of differences in the protein content of other NOS isoforms or in the relative expression NOS1 splice variants. In line with these findings, transoesophageal atrial burst pacing revealed no difference in AF susceptibility between mdx mice and their wild type littermates. Dystrophin depletion is not associated with atrial miR-31 upregulation, reduced NOS activity or increased AF susceptibility in the mdx mouse. Compared with the skeletal muscle, the milder atrial biochemical phenotype may explain why patients with DMD do not exhibit a higher prevalence of atrial arrhythmias despite a reduction in NOS1 content.

Differential Expression of Nnos Mrna and Nnos Protein in Normal and Duchenne Muscular Dystrophic Muscles

Abnormal Expression of Inducible Nitric Oxide Synthase in Duchenne Muscular Dystrophy Muscles

Decreased myocardial nNOS, increased iNOS and abnormal ECGs in mouse models of Duchenne muscular dystrophy

Expression of Nitric Oxide and Superoxide Dismutase in Skeletal Muscle of Children with Duchenne Muscular Dystrophy Patients

Depressed nNOS expression during spine transition in the developing hippocampus of FMR1 KO mice.

Diagnostic Value of Neuronal Nitric Oxide Synthase Antibody for Clinically Suspected Becker Muscular Dystrophy

Altered Bone-Regulating Myokine Expression In Skeletal Muscle Of Duchenne Muscular Dystrophy Mouse Models

Nitrosative stress elicited by nNOSµ delocalization inhibits muscle force in dystrophin-null mice.

Differential and constitutive expression of neuronal, inducible, and endothelial nitric oxide synthase mRNAs and proteins in pathologically normal human tissues.

Sarcolemmal Nnos Anchoring Reveals a Qualitative Difference Between Dystrophin and Utrophin

Why is early-onset atrial fibrillation uncommon in patients with Duchenne Muscular Dystrophy? Insights from the mdx mouse

Inos Ablation Does Not Improve Specific Force Of The Extensor Digitorum Longus Muscle In Dystrophin-Deficient Mdx4cv Mice

Changes of Dystrophin Expression in Muscle of Patients with DMD and Its Relevance to Clinical Pathology

Identification of Auxiliary Biomarkers and Description of the Immune Microenvironmental Characteristics in Duchenne Muscular Dystrophy by Bioinformatical Analysis and Experiment

Molecular Pathogenesis of Genetic and Inherited Diseases Preservation of Muscle Force in Mdx3cv Mice Correlates with Low-Level Expression of a Near Full-Length Dystrophin Protein

Differential expression profiling between the relative normal and dystrophic muscle tissues from the same LGMD patient

Identification and analysis of differentially expressed lncRNAs and their ceRNA networks in DMD/mdx primary myoblasts

microRNA and mRNA expression networks in Duchenne muscular dystrophy

Degenerative and Regenerative Pathways Underlying Duchenne Muscular Dystrophy Revealed by Single-Nucleus RNA Sequencing.

Increase in cathepsin K gene expression in Duchenne muscular dystrophy skeletal muscle

Behavioral, Biochemical and Pathological Characterization of a New MDX Mouse Model of Duchenne Muscular Dystrophy